This is the first genetic and immune checkpoint landscape of a PDX model of the pediatric HGG in the context of a constitutive mismatch repair deficiency patient associated with germline biallelic MSH6 inactivation, which could be an instrumental tool for exploring alternative therapeutic strategies. This evidence concerns the gene MSH6 and mismatch repair cancer syndrome 1.